Literature DB >> 8558725

Exercise training improves functional status in patients with peripheral arterial disease.

J G Regensteiner1, J F Steiner, W R Hiatt.   

Abstract

PURPOSE: In patients with intermittent claudication (IC) a structured walking exercise program improves exercise performance. However, few studies have evaluated the effects of exercise training on functional status during daily activities. We hypothesized that a supervised exercise training program would improve functional status in patients with IC, with 24 weeks of training more beneficial than 12 weeks. A secondary aim was to evaluate the effects of strength training and combinations of strength and treadmill training on functional status.
METHODS: Twenty-nine men with disabling IC were randomized to 12 weeks of either supervised treadmill training (3 hr/wk at a work intensity sufficient to produce claudication), strength training (3 hr/wk of resistive training of six muscle groups of each leg), or to a nonexercising control group. Functional status was assessed by questionnaires characterizing walking ability (Walking Impairment Questionnaire, WIQ), habitual physical activity level (Physical Activity Recall, PAR), and physical, social, and role functioning, well-being, and overall health (Medical Outcomes Study SF-20, MOS). Patients alos had their activity levels monitored with an activity monitor (Vitalog).
RESULTS: After 12 weeks of treadmill training PAR scores increased by 48 metabolic equivalent hr/wk, the MOS physical functioning score by 24 percentage points, and the number of bouts of walking activity measured by the Vitalog by 4.5 bouts/hr (all p < 0.05). No changes were seen in WIQ scores. After 12 additional weeks of treadmill training improvements initially observed in the PAR, MOS, and Vitalog scores were maintained, and in addition the ability to walk distances (WIQ) improved by 31 percentage points, and the IC severity score had improved by 29 percentage points (both p < 0.05). After 12 weeks of strength training patients improved their WIQ walking speed, stair climbing scores, and MOS well-being scores with no other changes in functional status. Subjects in the control group did not improve functional status by any measure. Twelve weeks of treadmill training after the strength training program maintained WIQ walking speed scores, and activity level defined by Vitalog improved. Twelve weeks of combined treadmill and strength training after the control period had no effect on functional status.
CONCLUSIONS: A supervised treadmill training program improved functional status during daily activities, with 24 weeks more effective than 12. In addition, treadmill training alone was more effective in improving functional status in patients with IC than strength training or combinations of the training modalities.

Entities:  

Mesh:

Year:  1996        PMID: 8558725     DOI: 10.1016/s0741-5214(05)80040-0

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  84 in total

1.  Walking exercise in patients with intermittent claudication. Experience in routine clinical practice.

Authors:  Marie-Louise Bartelink; Henri E J H Stoffers; Cornelis J Biesheuvel; Arno W Hoes
Journal:  Br J Gen Pract       Date:  2004-03       Impact factor: 5.386

2.  Comparison of walking with poles and traditional walking for peripheral arterial disease rehabilitation.

Authors:  Eileen G Collins; Susan Oʼconnell; Conor McBurney; Christine Jelinek; Jolene Butler; Domenic Reda; Ben S Gerber; Christopher Hurt; Mark Grabiner
Journal:  J Cardiopulm Rehabil Prev       Date:  2012 Jul-Aug       Impact factor: 2.081

3.  Meta-analysis of patient education interventions to increase physical activity among chronically ill adults.

Authors:  Vicki S Conn; Adam R Hafdahl; Sharon A Brown; Lori M Brown
Journal:  Patient Educ Couns       Date:  2007-11-26

4.  Supervised exercise for intermittent claudication - an under-utilised tool.

Authors:  Joseph Shalhoub; Maher Hamish; Alun H Davies
Journal:  Ann R Coll Surg Engl       Date:  2009-06-25       Impact factor: 1.891

5.  Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.

Authors:  W Todd Cade
Journal:  Phys Ther       Date:  2008-09-18

6.  A single bout of resistance exercise does not modify cardiovascular responses during daily activities in patients with peripheral artery disease.

Authors:  Lausanne B C C Rodrigues; Cláudia L M Forjaz; Aluísio H R A Lima; Alessandra S Miranda; Sérgio L C Rodrigues; Crivaldo G Cardoso; Dario Sobral Filho; Maria F Monteiro; Silvana L Gomes; Andrew W Gardner; Wagner L Prado; Raphael M Ritti-Dias
Journal:  Blood Press Monit       Date:  2014-04       Impact factor: 1.444

7.  The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model.

Authors:  Kelly P Downing; Kevin T Nead; Yoko Kojima; Themistocles Assimes; Lars Maegdefessel; Thomas Quertermous; John P Cooke; Nicholas J Leeper
Journal:  Vasc Med       Date:  2013-12-09       Impact factor: 3.239

Review 8.  Optimising exercise training in peripheral arterial disease.

Authors:  Andrew C Bulmer; Jeff S Coombes
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study.

Authors:  Timothy P Murphy; Donald E Cutlip; Judith G Regensteiner; Emile R Mohler; David J Cohen; Matthew R Reynolds; Joseph M Massaro; Beth A Lewis; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Michael R Jaff; Anthony J Comerota; Michael W Steffes; Ingrid H Abrahamsen; Suzanne Goldberg; Alan T Hirsch
Journal:  J Am Coll Cardiol       Date:  2015-03-17       Impact factor: 24.094

Review 10.  The effect of exercise on fitness and performance-based tests of function in intermittent claudication: a systematic review.

Authors:  Belinda J Parmenter; Jacqueline Raymond; Maria A Fiatarone Singh
Journal:  Sports Med       Date:  2013-06       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.